Prophase Labs Stock Short Ratio
| PRPH Stock | USD 0.75 0.01 1.35% |
ProPhase Labs fundamentals help investors to digest information that contributes to ProPhase Labs' financial success or failures. It also enables traders to predict the movement of ProPhase Stock. The fundamental analysis module provides a way to measure ProPhase Labs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ProPhase Labs stock.
ProPhase | Short Ratio |
ProPhase Labs Company Short Ratio Analysis
ProPhase Labs' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current ProPhase Labs Short Ratio | 7.04 X |
Most of ProPhase Labs' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ProPhase Labs is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ProPhase Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for ProPhase Labs is extremely important. It helps to project a fair market value of ProPhase Stock properly, considering its historical fundamentals such as Short Ratio. Since ProPhase Labs' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ProPhase Labs' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ProPhase Labs' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
ProPhase Discontinued Operations
Discontinued Operations |
|
Based on the latest financial disclosure, ProPhase Labs has a Short Ratio of 7.04 times. This is 80.51% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The short ratio for all United States stocks is 76.0% lower than that of the firm.
ProPhase Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ProPhase Labs' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ProPhase Labs could also be used in its relative valuation, which is a method of valuing ProPhase Labs by comparing valuation metrics of similar companies.ProPhase Labs is currently under evaluation in short ratio category among its peers.
ProPhase Labs Institutional Holders
Institutional Holdings refers to the ownership stake in ProPhase Labs that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of ProPhase Labs' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ProPhase Labs' value.| Shares | Bank Of America Corp | 2024-06-30 | 36.7 K | Bridgeway Capital Management, Llc | 2024-09-30 | 23.1 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 17.3 K | Commonwealth Equity Services Inc | 2024-06-30 | 13.4 K | Barclays Plc | 2024-06-30 | 11.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 8.8 K | Simplex Trading, Llc | 2024-06-30 | 3.2 K | Jamison Private Wealth Management Inc | 2024-09-30 | 3 K | Advisor Group Holdings, Inc. | 2024-06-30 | 2 K | Vanguard Group Inc | 2024-09-30 | 655.9 K | Renaissance Technologies Corp | 2024-09-30 | 215.1 K |
ProPhase Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (3.16) % | ||||
| Current Valuation | 47.45 M | ||||
| Shares Outstanding | 23.87 M | ||||
| Shares Owned By Insiders | 14.33 % | ||||
| Shares Owned By Institutions | 7.63 % | ||||
| Number Of Shares Shorted | 154.06 K | ||||
| Price To Earning | 6.59 X | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 0.99 X | ||||
| Revenue | 44.38 M | ||||
| Gross Profit | 70.65 M | ||||
| EBITDA | (14.83 M) | ||||
| Net Income | (16.78 M) | ||||
| Cash And Equivalents | 27.5 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 21.38 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | (11.35 M) | ||||
| Short Ratio | 7.04 X | ||||
| Earnings Per Share | (1.53) X | ||||
| Target Price | 18.5 | ||||
| Number Of Employees | 113 | ||||
| Beta | -0.095 | ||||
| Market Capitalization | 17.77 M | ||||
| Total Asset | 91.93 M | ||||
| Retained Earnings | (5.03 M) | ||||
| Working Capital | 26.73 M | ||||
| Current Asset | 9.73 M | ||||
| Current Liabilities | 6.25 M | ||||
| Net Asset | 91.93 M |
About ProPhase Labs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProPhase Labs's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProPhase Labs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProPhase Labs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out ProPhase Labs Piotroski F Score and ProPhase Labs Altman Z Score analysis. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share 0.996 | Quarterly Revenue Growth (0.81) | Return On Assets (0.23) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.